±ÙħÀ±¼º ¹æ±¤¾Ï ȯÀÚÀÇ ¹æ±¤ º¸Á¸Àû Ä¡·á °á°ú
Bladder Preserving Treatment in Patients with Muscle Invasive Bladder Cancer
À¯Á¤ÀÏ, ÀÓÈ£¿µ, ÃÖÇÑ¿ë, Çã½ÂÀç, ¾È¿ëÂù, ÀÌÇö¹«, ±è¿ø¼®, ¹Ú¿ø, ¿Àµ¿·Ä, Àü¼º¼ö, ÀÓµµÈÆ,
¼Ò¼Ó »ó¼¼Á¤º¸
À¯Á¤ÀÏ ( Yu Jeong-Il )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
ÀÓÈ£¿µ ( Lim Ho-Yeong )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú
ÃÖÇÑ¿ë ( Choi Han-Yong )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
Çã½ÂÀç ( Huh Seung-Jae )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
¾È¿ëÂù ( Ahn Yong-Chan )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ´ëÀå¼¾ÅÍ ¿Ü°úÇб³½Ç
ÀÌÇö¹« ( Lee Hyun-Moo )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±è¿ø¼® ( Kim Won-Seog )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú
¹Ú¿ø ( Park Won )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
¿Àµ¿·Ä ( Oh Dong-Ryol )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
Àü¼º¼ö ( Jeon Seong-Soo )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ºñ´¢±â°úÇб³½Ç
ÀÓµµÈÆ ( Lim Do-Hoon )
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
KMID : 0859320070250020070
Abstract
¸ñ Àû: ±ÙħÀ±¼º ¹æ±¤¾ÏÀ¸·Î Áø´Ü¹Þ°í ¹æ±¤ º¸Á¸Àû Ä¡·á¸¦ ½ÃÇà¹ÞÀº ȯÀÚ¸¦ ´ë»óÀ¸·Î Á¾¾ç ¹ÝÀÀ Á¤µµ ¹× »ýÁ¸À²À» ºÐ¼®ÇÏ°í ÀÌ¿¡ ¿µÇâÀ» ÁÖ´Â ¿¹ÈÄ ÀÎÀÚ¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý: 1995³â 9¿ùºÎÅÍ 2004³â 6¿ù±îÁö »ï¼º¼¿ïº´¿ø¿¡¼ ¹æ±¤¾ÏÀ¸·Î Áø´Ü ¹Þ°í ¹æ±¤ º¸Á¸Àû Ä¡·á¸¦ ¹ÞÀº ȯÀÚ 39¸í Áß ÆíÆò»óÇÇ¾Ï È¯ÀÚ 1¸í°ú ¼±¾Ï ȯÀÚ 1¸íÀ» Á¦¿ÜÇÑ 37¸íÀÇ È¯ÀÚ¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ¼ºº°·Î´Â ³²³à°¡ °¢°¢ 33¸í, 4¸íÀ̾úÀ¸¸ç ¿¬·ÉÀº 38¡86¼¼(Áß¾Ó°ª 67¼¼)¿´´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¸ðµÎ ÀÌÇà»óÇǾÏÀ̾ú´Ù. ÀÓ»óÀûÀ¸·Î ¿ø¹ß º´¼Ò º´±â´Â T2, T3, T4°¡ °¢°¢ 19¸í, 13¸í, 5¸íÀ̾ú´Ù. °æ¿äµµ¹æ±¤ÀýÁ¦¼ú(TURB) ½Ã ¿ÏÀü ÀýÁ¦¿Í ºÎºÐ ÀýÁ¦°¡ °¢°¢ 17¸í°ú 19¸í¿¡¼ ½ÃÇàµÇ¾ú°í, Á¶Á÷ °Ë»ç¸¸ ½ÃÇàµÈ °æ¿ì°¡ 1¸í ÀÖ¾ú´Ù. Ç×¾ÏÈÇйæ»ç¼±º´¿ë¿ä¹ýÀ» ¹ÞÀº ȯÀÚ°¡ 24¸í, À¯µµ Ç×¾ÏÈÇпä¹ý ÈÄ ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº ȯÀÚ°¡ 8¸í, ¹æ»ç¼± Ä¡·á¸¸ ¹ÞÀº ȯÀÚ°¡ 6¸íÀ̾ú°í º¸Á¶Ç×¾ÏÈÇпä¹ýÀ» ½ÃÇà¹ÞÀº ȯÀÚ°¡ 18¸íÀ̾ú´Ù. ¹æ»ç¼± Ä¡·á´Â 10¡15 MV ±¤ÀÚ¼±À» »ç¿ëÇÏ¿´À¸¸ç ÇÏ·ç¿¡ 1.8¡2.0 Gy·Î Àü°ñ¹ÝÀ» ´ë»óÀ¸·Î 45¡46 Gy¸¦ 4¹® Á¶»çÇÑ ÈÄ ¹æ±¤¿¡¸¸ ±¹ÇÑÇÏ¿© 3Â÷¿ø ÀÔüÁ¶ÇüÄ¡·á·Î 10.8¡22.0 Gy (Áß¾Ó°ª 19.8 Gy) Ãß°¡ÇÏ¿© ÃÑ 55.8¡67 Gy (Áß¾Ó°ª 64.8 Gy)¸¦ Á¶»çÇÏ¿´´Ù. Ç×¾ÏÈÇÐÄ¡·á´Â CisplatinÀ» ±âº»À¸·Î ÇÏ¿© 2¡6ȸ(Áß¾Ó°ª 3ȸ) ½ÃÇàÇÏ¿´´Ù. °¢ º¯¼ö °£ÀÇ »ó°ü °ü°è ºÐ¼®Àº Chi-Square test¸¦ ÀÌ¿ëÇÏ¿´´Ù. »ýÁ¸À²Àº Kaplan-Meier ¹ýÀ¸·Î »êÃâÇÏ¿´°í µÎ ±º °£ÀÇ ºñ±³´Â Log-rank test ÀÌ¿ëÇÏ¿´´Ù. »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀεéÀÇ ´Ùº¯·® ºÐ¼®Àº Cox ºñ·ÊÀ§Çè ¸ðµ¨À» ÀÌ¿ëÇÏ¿´´Ù. À¯ÀǼöÁØ 0.05 ¹Ì¸¸À» ÀǹÌÀÖ´Â °ÍÀ¸·Î ÆÇ´ÜÇÏ¿´´Ù.
°á °ú: Ä¡·á ¹ÝÀÀ Æò°¡´Â Ä¡·á Á¾·á ÈÄ 3°³¿ù ÀüÈÄ¿¡ ½ÃÇàÇÑ ¿ä¼¼Æ÷ °Ë»ç, ¹æ±¤ ³»½Ã°æ ¼Ò°ß ¹× º¹ºÎ°ñ¹Ý Àü»êÈ´ÜÃþÃÔ¿µÀ» Á¾ÇÕÇÏ¿© ÆÇ´ÜÇÏ¿´´Âµ¥, ¿ÏÀü °üÇØ, ºñ¿ÏÀü °üÇØ°¡ °¢°¢ 16¸í(43%), 20¸í(54%)À̾ú´Ù. ´ë»ó ȯÀÚÀÇ 3³â Àüü »ýÁ¸À²Àº 54.7%¿´°í Áß¾Ó »ýÁ¸ ±â°£Àº 54°³¿ù(3¡91°³¿ù)À̾ú´Ù. 3³â ¹«ÁøÇà »ýÁ¸À²Àº 37.2%¿´´Ù. ÃßÀû °üÂû Áß 24¸í(64.9%)ÀÌ Àç¹ßÇÏ¿´´Âµ¥ ±¹¼Ò Àç¹ßÀÌ 17¸í(46%), ¿ø°Ý ÀüÀÌ°¡ 6¸í(16%), ±¹¼Ò Àç¹ß°ú ¿ø°Ý ÀüÀÌ°¡ µ¿½Ã¿¡ ³ªÅ¸³ °æ¿ì°¡ 1¸í(3%) ÀÖ¾ú´Ù. ±¹¼Ò Àç¹ßÀÇ ±¸Á¦ ¿ä¹ýÀ¸·Î ±ÙÄ¡Àû ¹æ±¤ÀýÁ¦¼úÀÌ ½ÃÇàµÈ °æ¿ì´Â ¾ø¾ú°í TURB¸¸ ½ÃÇàÇϰųª Ç×¾ÏÈÇÐÄ¡·á°¡ º´ÇàµÇ±âµµ ÇÏ¿´´Ù. Ä¡·á ÈÄÀÇ ¹ÝÀÀ Á¤µµ°¡ Àüü »ýÁ¸À²(p=0.006)°ú ¹«ÁøÇà »ýÁ¸À²(p=0.001)¿¡ Åë°èÀûÀ¸·Î ÀǹÌÀÖ´Â ÀÎÀÚ¿´°í, TURBÀÇ Á¤µµ°¡ Àüü »ýÁ¸À²(p=0.091)°ú ¹«ÁøÇà »ýÁ¸À²(p=0.081), ¹æ»ç¼± Á¶»ç¼±·®ÀÌ ¹«ÁøÇà »ýÁ¸À²(p=0.07)¿¡¼ Åë°èÀû ÀÇÀÇ¿¡ Á¢±ÙÇÏ¿´´Ù.
°á ·Ð: ¹æ±¤ º¸Á¸Àû Ä¡·á ½Ã Ä¡·á ÈÄ ¹ÝÀÀ Á¤µµ°¡ Àüü »ýÁ¸À²°ú ¹«ÁøÇà »ýÁ¸À²¿¡ ÀÖ¾î Áß¿äÇÑ ¿¹ÈÄ ÀÎÀÚÀÓÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. ¶ÇÇÑ, TURB¸¦ °¡´ÉÇÑ ÃæºÐÈ÷ ½ÃÇàÇÏ°í º´¼Ò ºÎÀ§¿¡ ¹æ»ç¼± Á¶»ç¼±·®À» ³ôÀÌ´Â °ÍÀÌ ¹æ±¤º¸Á¸ Ä¡·á¿¡¼ Áß¿äÇϸ®¶ó »ý°¢µÈ´Ù. ±×¸®°í, ¹æ±¤º¸Á¸ Ä¡·á ÈÄ Ä¡·á ¹ÝÀÀ ÆÇÁ¤¿¡¼ ¿ÏÀü °üÇØ°¡ ¿ÀÁö ¾ÊÀº °æ¿ì´Â ¼ö¼ú µîÀÇ Àû±ØÀûÀÎ ±¸Á¦ Ä¡·á°¡ ÇÊ¿äÇÏ°Ú´Ù. ÇâÈÄ ¹æ±¤ º¸Á¸À» À§ÇÑ Ç×¾ÏÈÇÐ ¹æ»ç¼± º´¿ëÄ¡·á ÇÁ·ÎÅäÄÝ¿¡ µû¸¥ ÀÓ»ó °æÇèÀ» ´õ ½×¾Æ¾ß ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.
Purpose: This study analyzed the tumor response, overall survival, progression free survival and related prognostic factors in patients with muscle invasive bladder cancer subjected to bladder preserving treatment.
Materials and Methods: Between August 1995 and June 2004, 37 patients with muscle invasive (transitional cell carcinoma, clinically stage T2-4) bladder cancer were enrolled for the treatment protocol of bladder preservation. There were 33 males and 4 females, and the median age was 67 years (range 38¡86 years). Transurethral resection of the bladder (TURB) was performed in 17 patients who underwent complete resection. The median radiation dose administered was 64.8 Gy (range 55.8¡67 Gy). The survival rate was calculated by the Kaplan-Meier method.
Results: An evaluation of the response rate was determined by abdomen-pelvic CT and cystoscopy at three months after radiotherapy. A complete response was seen in 17 patients (46%). The survival rate at three years was 54.7%, with 54 months of median survival (range 3¡91 months). During the study, 17 patients died and 13 patients had died from bladder cancer. The progression free survival rate at three years was 37.2%. There were 24 patients (64.9%) who had disease recurrence: 16 patients (43.2%) had local recurrence, 6 patients (16.2%) had a distant recurrence, and 2 patients (5.4%) had both a local and distant recurrence. The survival rate (p=0.0009) and progression free survival rates (p=0.001) were statistically significant when compared to the response rate after radiotherapy.
Conclusion: The availability of complete TURB and appropriate chemoradiotherapy were important predictors for bladder preservation and survival.
Å°¿öµå
¹æ±¤¾Ï; ¹æ±¤ º¸Á¸Àû Ä¡·á; ¹æ»ç¼± Ä¡·á
Bladder cancer; Bladder preserving teratment; Radiotherapy
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸